Specific immunotherapy in allergic asthma;Die bedeutung der spezifischen immuntherapie bei allergischem asthma bronchiale

Deutsche Medizinische Wochenschrift

Volumn 128, Issue 5, 2003, Pages 204-209

  Gillissen, A ^a   Bergmann, K C ^b   Kleine Tebbe, J ^c   Schultze Werninghaus, G ^d   Virchowjun, J C ^e   Wahn, U ^f   Schulenburg, J M Graf V D ^a  

^a Robert Koch Klinik   (Germany)

^b Allergie und Asthma Klinik   (Germany)

^c Universitätsklinik der Ruhr Universität Bochum ^*

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f LEIBNIZ UNIVERSITY HANNOVER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; GRASS POLLEN EXTRACT; HOUSE DUST ALLERGEN;

ALLERGIC ASTHMA; ALLERGIC REACTION; ANAPHYLACTIC SHOCK; ANTIGEN SPECIFICITY; DRUG CONTRAINDICATION; DRUG COST; DRUG INDICATION; HUMAN; IMMUNOTHERAPY; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PROPHYLAXIS; REVIEW; RHINOCONJUNCTIVITIS; RISK BENEFIT ANALYSIS;

ALLERGENS; ASTHMA; COST-BENEFIT ANALYSIS; HUMANS; IMMUNOTHERAPY; PATIENT COMPLIANCE; T-LYMPHOCYTES;

EID: 0037474232     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-36983     Document Type: Review

References (53)

1. Abramson M, Puy R, Weiner J. Immunotherapy in asthma: an updated systematic review. Allergy 1999; 54:1022-1041
2. Adkinson NF, Eggleston PA, Eney D et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997; 336:324-331
3. Akdis CA, Blaser K. Regulation of specific immune responses by chemical and structural modifications of allergens. Int Arch Allergy Appl Immunol 2000; 121:261-269
4. Bergmann K-C, Wolf H, Schnitker J et al. Lebensqualität und Compliance von Patienten bei der spezifischen Immuntherapie mit Gräser- und Roggenallergen (LQC-Studie). Allergo J 2000; 9:480-488
5. Borish LC, Nelson HS, Bensch G et al. Phase I/II study of soluble interleukin-4 receptor (IL-4R) in adults with moderate asthma (abst.). Eur Respir J 1999; 14:288s
6. Bosley CM, Parry OT, Cochrane GM. Patient compliance with inhaled medication: does combining beta-agonists with corticosteroids improve compliance? Eur Respir J 1994; 7:504-509
7. Bousquet J, Demoly P, Michel FB. Specific immunotherapy in rhinitis and asthma. Ann Allergy Asthma Immunol 2001; 87:38-42
8. Bousquet J, Hejjaoui A, Becker WM et al. Clinical and immunologic reactivity of patients allergic to grass pollens and to multiple pollen species. I. Clinical and immunologic characteristics. J Allergy Clin Immunol 1991; 87:737-746
9. Bousquet J, Lockey RF, Malling H-J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998; 53:1-42
10. Buston KM, Wood SF. Non-compliance amongst adolescents with asthma: listening to what they tell us about self-management. Fam Pract 2000; 17:134-138
11. Cookson W. The alliance of genes and environment in asthma and allergy. Nature 1999; 402:5-11
12. Corren J. The impact of allergic rhinitis on bronchial asthma. J Allergy Clin Immunol 1998; 101:352-356
13. Creticos PS. The consideration of immunotherapy in the treatment of allergic asthma. J Allergy Clin Immunol 2000; 105:559-574
14. Creticos PS. The consideration of immunotherapy in he treatment of allergic asthma. Ann Allergy Asthma Immunol 2001; 87:13-27
15. Durham SK, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468-475
16. Durham SR, Ying S, Varney VA et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996; 97:1356-1365
17. Hakansson L, Heinrich C, Rak S et al. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. J Allergy Clin Immunol 1997; 99:551-562
18. Hamid QA, Schotman E, Jacobson MR et al. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997; 99:254-260
19. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standarized, partially purified extract of haous dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 2002; 91:709-722
20. Hedlin G, Wille S, Browaldh L et al. Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and pharmacotherapy. J Allergy Clin Immunol 1999; 103:609-614
21. Horst M, Hejjaoui A, Michel FB et al. Double-blind, placebo-controlled rush immunotherapy with a standarized alternaria extract. J Allergy Clin Immunol 1990; 85:460-472
22. Jacobson L, Nüchel PB, Wihl JA et al. Immunotherapy with partially purified and standarized tree pollen extracts. IV. Results from long-term (6-year) follow-up. Allergy 1997; 52:914-920
23. Johnstone DE, Dutton A. The value of hyposensitization therapy for bronchial asthma in children - a 14-year study. Pediatrics 1968; 42:793-802
24. Jutel M, Pichler WJ, Skrbic D et al. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995; 154:4187-4194
25. Kleine-Tebbe J, Fuchs T, Klimek L et al. Die spezifische Immuntherapie (Hyposensibilisierung) mit Allergenen. Allergo Journal 2000; 9:317-324
26. Kroegel C, Herzog V, Förster M, Braun R. Pathogenetische Grundlagen des Asthma bronchiale. Stuttgart: Georg Thieme Verlag, 1. Aufl, In: Kroegel C (Hrsg.): Asthma bronchiale. 1998; 13-51
27. Lockey RF. "ARIA": global guidelines and new forms of allergen immunotherapy. J Allergy Clin Immunol 2001; 108:497-499
28. Malling H-J, Djurup R, Sondergaard J et al. Immunotherapy. Position paper of the European Academy of Allergology and Clinical Immunology (EAAC1). Allergy 1985; 40:702-709
29. Malling H-J, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with cladosporium herbarum. Allergy 1989; 41:507-519
30. Märtens P, Lobermeyer K. Krankheitskosten-Studie und Kosten-Nutzen-Analyse der spezifischen Immuntherapie bei Asthma. Allergo Journal 2001; 10:341-347
31. Melen E, Wickman M, Nordvall SL et al. Influence of early and current environmental exposure factors on sensitization and outcome of asthma in preschool children. Allergy 2001; 56:646-652
32. More DR, Hagan LL. Factors affecting compliance with allergen immunotherapy at a military medical center. Ann Allergy Asthma Immunol 2002; 88:391-394
33. Möller Ch, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (The PAT-Study). J Allergy Clin Immunol 2002; 109:251-256
34. National Institutes of Health (Hrsg). Global strategy for asthma management and prevention NHLBI/WHO Workshop report. Bethesda, USA: U.S. Department of Health and Human Services, 2002; 1-176
35. Olaguibel JM, Tabar AI, Garcia BE et al. Long-term immunotherapy with on optimal maintenance dose of a standarized Dermatophagoides pteronyssinus extract in asthmatic patients. Invest Allergol Clin Immunol 1999; 9:110-116
36. Olsen OT, Larsen KR, Jacobson L et al. A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 1997; 52:853-859
37. Pajno GB, Barberio G, De Luca F et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergol 2001; 31:1392-1397
38. Pichler CE, Marquardsen A, Sparholt S et al. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinaei results in decreased bronchial hyperreactivity. Allergy 1997; 52:274-283
39. Pichler CE, Pichler WJ. Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy 2001; 56:301-306
40. Rak S. Effects of immunotherapy on the inflammation in pollen asthma. Allergy 1993; 48:125-128
41. Rak S, Björnson A, Hakansson L et al. The effect of immunotherapy on eosinophil accumulation and production of eosinophil chemotactic activity in the lung of subjects with asthma during natural pollen exposure. J Allergy Clin Immunol 1991; 88:878-888
42. Renz H. Immuntherapie bei breitem Allergiespektrum. Dtsch Med Wochenschr 2002; 127:1274-1275
43. Rhodes BJ. Patients dropouts before completion of optimal dose, multiple allergen immunotherapy. Ann Allergy Asthma Immunol 1999; 82:281-286
44. Schädlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 2000; 17:37-52
45. Schoenwetter WT. Safe allergen immunotherapy. The correct allergen, the apporpriate patient, the adequate dose. Postgrad Med 1996; 100:123-126
46. Schultze-Werninghaus G. Wirksame Therapieoptionen bei Insektengiftallergien, Rhinokonjunktivitis und Asthma. Klinikarzt 2000; 5:132-136
47. Sennekamp J, Kersten W, Hornung B. Empfehlungen zur Hyposensibilisierung mit Allergenextrakten. Allergo J 1995; 4:205-212
48. Varney VA, Gaga M, Frew AJ et al. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. Br Med J 1991; 302:265-269
49. Varney VA, Hamid Q, Gaga M et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 2001; 92:644-651
50. Wahn U. Do asthmatic children benefit from specific immunotherapy. Clin Exp Allergy 1999; 29:143
51. Walker SM, Pajno GB, Lima MT et al. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 2001; 107:87-93
52. Walker SM, Varney VA, Gaga M et al. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy 1995; 50:405-413
53. Wettengel R, Berdel D, Hofmann D et al. Asthmatherapie bei Kindern und Erwachsenen. Empfehlungen der Deutschen Atemwegsliga in der Deutschen Gesellschaft für Pneumologie. Med Klin 1998; 93:639-650